Cabergoline 1 - John Lee

Cabergoline, known under the trade name Dostinex, is an ergot-derived pharmaceutical introduced in the 1980s by Pharmacia. It works by activating dopamine D2 receptors, effectively inhibiting prolactin secretion from the pituitary gland. This action has made it a treatment of choice for prolactin-secreting adenomas. U.S. market exclusivity ended when generics were approved from 2005 to 2007. It’s now widely prescribed in over 30 countries, maintaining relevance in both clinical endocrinology and select off-label hormonal interventions.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Cabergoline 1 by John Lee, consult with your doctor or healthcare professional.